BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36507722)

  • 1. Nomograms to predict progression of disease within 24 months in patients with localized natural killer/T-cell lymphoma.
    Li N; Jiang M; Wu WC; Zou LQ
    Future Oncol; 2022 Oct; 18(32):3573-3583. PubMed ID: 36507722
    [No Abstract]   [Full Text] [Related]  

  • 2. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
    Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
    Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
    Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
    Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
    Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
    Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extranodal natural killer/T-cell lymphoma with hepatosplenic involvement: a retrospective study of a consecutive 14-year case series.
    Zhang YH; Li Z; Zhao S; Zhang WY; Liu QL; Liu WP; Gao LM
    Ann Hematol; 2023 Oct; 102(10):2803-2813. PubMed ID: 37434096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic Prediction of Survival for Sinonasal Extranodal Natural Killer/T-cell Lymphoma.
    Wang T; Qiu Y; Shi L; Chen D; Chen X; Liu J; Liu T
    Laryngoscope; 2023 Jul; 133(7):1645-1651. PubMed ID: 37294046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
    Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomograms based on SUVmax of
    Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
    Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
    Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
    Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
    Kim SJ; Kim JH; Ki CS; Ko YH; Kim JS; Kim WS
    Ann Oncol; 2016 Mar; 27(3):508-13. PubMed ID: 26658891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extranodal natural-killer/T-cell lymphoma, nasal type: An immunomorphological study from a regional cancer institute in India.
    Agrawal M; Champaka G; Amirtham U; Jacob LA; Premalata CS
    J Cancer Res Ther; 2022; 18(4):1137-1143. PubMed ID: 36149173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
    Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
    Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations in
    Gao LM; Zhao S; Zhang WY; Wang M; Li HF; Lizaso A; Liu WP
    Cancer Biol Ther; 2019; 20(10):1319-1327. PubMed ID: 31311407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome.
    Li N; Jiang M; Wu WC; Wei WW; Zou LQ
    Front Oncol; 2021; 11():704962. PubMed ID: 34490105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
    Feng Y; Jing C; Yu X; Cao X; Xu C
    Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
    Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
    Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients.
    Li K; Wang R; Huang S; Pan X; Chen H; Zhou L; Wei J; Wu C; Zhu X; Liang S; Qu S
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e537-e543. PubMed ID: 30243570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.